Viatris Change in Inventories 2010-2025 | VTRS
Viatris annual/quarterly change in inventories history and growth rate from 2010 to 2025. Change in inventories can be defined as the increase or decrease in a company's inventories for the period.
- Viatris change in inventories for the quarter ending March 31, 2025 was $-0.194B, a 47.71% decline year-over-year.
- Viatris change in inventories for the twelve months ending March 31, 2025 was $-2.164B, a 24.64% increase year-over-year.
- Viatris annual change in inventories for 2024 was $-0.723B, a 17.95% increase from 2023.
- Viatris annual change in inventories for 2023 was $-0.613B, a 136.34% increase from 2022.
- Viatris annual change in inventories for 2022 was $-0.26B, a 39.31% decline from 2021.
| Viatris Annual Change in Inventories (Millions of US $) |
|
|---|---|
| 2024 | $-723 |
| 2023 | $-613 |
| 2022 | $-260 |
| 2021 | $-428 |
| 2020 | $-742 |
| 2019 | $-513 |
| 2018 | $-548 |
| 2017 | $-130 |
| 2016 | $-279 |
| 2015 | $-320 |
| 2014 | $-148 |
| 2013 | $-157 |
| 2012 | $-172 |
| 2011 | $-221 |
| 2010 | $-95 |
| 2009 | $20 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.799B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $147.306B | 27.32 |
| CVS Health (CVS) | United States | $83.088B | 10.33 |
| Elevance Health (ELV) | United States | $65.860B | 8.86 |
| Cencora (COR) | United States | $56.044B | 18.67 |
| DiDi Global (DIDIY) | China | $26.733B | 28.40 |
| Labcorp Holdings (LH) | United States | $22.380B | 17.79 |
| Natera (NTRA) | United States | $21.934B | 0.00 |
| BioMerieux (BMXMF) | France | $17.238B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.271B | 0.00 |
| ICON (ICLR) | Ireland | $13.654B | 13.14 |
| CochLear (CHEOY) | Australia | $13.302B | 0.00 |
| Medpace Holdings (MEDP) | United States | $12.903B | 34.15 |
| Solventum (SOLV) | United States | $12.500B | 12.90 |
| Revvity (RVTY) | United States | $10.214B | 18.00 |
| Sonic Healthcare (SKHHY) | Australia | $9.176B | 0.00 |
| Avantor (AVTR) | United States | $8.631B | 12.66 |
| Caris Life Sciences,�Inc (CAI) | United States | $8.258B | 0.00 |
| HealthEquity (HQY) | United States | $8.040B | 35.22 |
| Charles River Laboratories (CRL) | United States | $7.517B | 14.26 |
| Bausch + Lomb (BLCO) | Canada | $4.874B | 32.79 |
| Sotera Health (SHC) | United States | $4.221B | 23.59 |
| Amplifon S.p.A (AMFPF) | Italy | $3.937B | 21.83 |
| BrightSpring Health Services (BTSG) | United States | $3.848B | 29.35 |
| GeneDx Holdings (WGS) | United States | $3.344B | 76.59 |
| Surgery Partners (SGRY) | United States | $2.946B | 37.06 |
| Alignment Healthcare (ALHC) | United States | $2.899B | 0.00 |
| Concentras Parent (CON) | United States | $2.871B | 18.21 |
| Organon (OGN) | United States | $2.353B | 2.56 |
| Premier (PINC) | United States | $1.978B | 15.01 |
| Progyny (PGNY) | United States | $1.873B | 39.60 |
| Ardent Health (ARDT) | United States | $1.785B | 6.89 |
| PACS (PACS) | United States | $1.705B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.282B | 8.56 |
| GoodRx Holdings (GDRX) | United States | $1.250B | 20.59 |
| Teladoc Health (TDOC) | United States | $1.214B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.974B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.965B | 0.00 |
| Embecta (EMBC) | United States | $0.779B | 4.56 |
| AMN Healthcare Services Inc (AMN) | United States | $0.676B | 8.36 |
| CareDx (CDNA) | United States | $0.663B | 12.22 |
| Performant Healthcare (PHLT) | United States | $0.602B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.583B | 200.00 |
| Nutex Health (NUTX) | United States | $0.534B | 8.08 |
| Omada Health (OMDA) | $0.497B | 0.00 | |
| So-Young (SY) | China | $0.488B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.485B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.480B | 0.00 |
| SBC Medicals (SBC) | United States | $0.470B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.467B | 10.52 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.405B | 0.00 |
| Enhabit (EHAB) | United States | $0.382B | 25.13 |
| Agilon Health (AGL) | United States | $0.369B | 0.00 |
| Oncology Institute (TOI) | United States | $0.367B | 0.00 |
| LifeMD (LFMD) | United States | $0.324B | 0.00 |
| Beauty Health (SKIN) | United States | $0.292B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.200B | 0.00 |
| DocGo (DCGO) | United States | $0.169B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.129B | 0.00 |
| KindlyMD (NAKA) | United States | $0.084B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.084B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Biodesix (BDSX) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.048B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.040B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.040B | 0.00 |
| ModivCare (MODV) | United States | $0.033B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.011B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.010B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |